← Leaderboards
Lucio H. Castilla
University Of Virginia
$7,520,870
Attributed
$11,777,271
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,777,271 · 7
By mechanism
R01$11,106,981 · 4
U01$485,790 · 1
R21$164,500 · 1
R13$20,000 · 1
Top collaborators
- John Hackett Bushweller9 shared
- Roger A Rajewski9 shared
- Monica L Guzman5 shared
Most similar at University Of Virginia
Same institution · by research overlap
- John Hackett Bushweller$17,127,098
- Roger A Rajewski$1,702,496
- Monica L Guzman$6,874,300
- Edward A Botchwey$8,169,626
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationLeukemiaGenesCore-Binding FactorMalignant NeoplasmsSelf-RenewalMouse ModelTranscription FactorBaseProgramsHematopoietic Stem CellsLeukemic CellCellsHematopoiesisChimeric ProteinsRunx1 GeneProgenitorMyh11 GeneMediatingCbfb GeneIn VivoApoptosisChromosomes, Human, Pair 16Relapse
Grant awards (26)
Study of tyrosine kinase inhibitors as preventive therapy in RUNX1-FPD$485,790
U01 · FY2025 · CA · contact PI
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$666,852
R01 · FY2023 · CA
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$667,159
R01 · FY2022 · CA
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$678,851
R01 · FY2021 · CA
Mechanisms of inv(16) acute myeloid leukemia$426,803
R01 · FY2021 · CA · contact PI
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$675,954
R01 · FY2020 · CA
Mechanisms of inv(16) acute myeloid leukemia$426,803
R01 · FY2020 · CA · contact PI
Targeted Small Molecule Inhibitors for Inv(16) Leukemia$716,817
R01 · FY2019 · CA
Mechanisms of inv(16) acute myeloid leukemia$413,998
R01 · FY2019 · CA · contact PI
Mechanisms of inv(16) acute myeloid leukemia$436,263
R01 · FY2018 · CA · contact PI
Mechanisms of inv(16) acute myeloid leukemia$426,803
R01 · FY2017 · CA · contact PI
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC$593,059
R01 · FY2013 · CA
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC$630,914
R01 · FY2012 · CA
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC$642,418
R01 · FY2011 · CA
Cooperating genes in inv (16) acute myeloid leukemia$321,949
R01 · FY2011 · CA · contact PI
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC$686,873
R01 · FY2010 · CA
Cooperating genes in inv (16) acute myeloid leukemia$331,906
R01 · FY2010 · CA · contact PI
Identification of CBFB-MYH11 specific inhibitors for acute myeloid leukemia$164,500
R21 · FY2010 · NS · contact PI
Cooperating genes in inv (16) acute myeloid leukemia$397,657
R01 · FY2009 · CA · contact PI
Cooperating genes in inv (16) acute myeloid leukemia$351,406
R01 · FY2008 · CA · contact PI
15th International RUNX Workshop$20,000
R13 · FY2008 · CA · contact PI
Cooperating genes in inv (16) acute myeloid leukemia$351,406
R01 · FY2007 · CA · contact PI
Cooperating genes in inv(16) acute myeloid leukemia$318,398
R01 · FY2005 · CA
Cooperating genes in inv(16) acute myeloid leukemia$318,398
R01 · FY2004 · CA
Cooperating genes in inv(16) acute myeloid leukemia$318,398
R01 · FY2003 · CA
Cooperating genes in inv(16) acute myeloid leukemia$307,896
R01 · FY2002 · CA